List Trials for Recurrent Multiple Myeloma

Multiple Myeloma

 

Yttrium Y 90 anti-CD45 monoclonal antibody BC8 + Chemo + TDI before Transplant for Multiple Myeloma (2450)
A Phase I Study of 90Y-BC8-DOTA monoclonal antibody, Fludarabine and TBI Followed by HLA-Matched, Allogeneic Peripheral Blood Stem Cell Transplant for the Treatment of Multiple Myeloma

Investigator: Damian J. Green;   Conditions: Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma;    Status: Recruiting;   Study ID: NCT01503242

SAR650984 for CD38+ Hematological Malignancies
Dose Escalation Safety and Pharmacokinetic Study of Multiple Intravenous Administrations of a Humanized Monoclonal Antibody (SAR650984) Against CD38 In Patients With Selected CD38+ Hematological Malignancies

Investigator: Damian J. Green, MD;   Conditions: Hematological Malignancies;    Status: Recruiting;   Study ID: NCT01084252

MK-3475 for Hematologic Malignancies
A Phase Ib Multi-Cohort Trial of MK-3475 in Subjects With Hematologic Malignancies

Investigator: Damian J. Green, MD;   Conditions: Myelodysplastic Syndrome, Multiple Myeloma, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma;    Status: Pending;   Study ID: NCT01953692

GSK2857916 for Relapsed/Refractory Multiple Myeloma (20142069)
A Phase I Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of the Antibody Drug Conjugate GSK2857916 in Subjects with Relapsed/Refractory Multiple Myeloma and Other Advanced Hematologic Malignancies Expressing BCMA

Investigator: Edward Libby, MD;   Conditions: Multiple Myeloma;    Status: Recruiting;   Study ID: NCT02064387

Three Dose Schedules of Daratumumab for Smoldering Multiple Myeloma
A Randomized Phase 2 Trial to Evaluate Three Daratumumab Dose Schedules in Smoldering Multiple Myeloma

Investigator: Edward Libby;   Conditions: Multiple Myeloma;    Status: Recruiting;   Study ID: NCT02316106

Pomalidomide/Dexamethasone With or Without Elotuzumab for Multiple Myeloma (20160970)
An Open Label, Randomized Phase 2 Trial of Pomalidomide/Dexamethasone With or Without Elotuzumab in relapsed and refractory Multiple Myeloma

Investigator: Pamela Becker, MD, PhD;   Conditions: Hematologic Malignancies; Lymphoproliferative Disorders; Multiple Myeloma;    Status: Recruiting;   Study ID: NCT02654132